AI Article Synopsis
- Therapy-induced senescence (TIS) may lead to therapy resistance but also has potential benefits in boosting anti-tumor immunity through senescent cells (SnCs).
- The protocol outlines how to isolate and differentiate CD103 dendritic cells (DCs) from mouse bone marrow, induce senescence in colon cancer cells, and co-culture these DCs with SnCs.
- It includes detailed instructions for analyzing the maturation and activation of DCs using flow cytometry, referencing previous studies for deeper insights.
Article Abstract
Therapy-induced senescence (TIS) may contribute to therapy resistance; however, evidence also suggests that senescent cells (SnCs) may promote anti-tumor immunity. Here, we present a protocol for examining the capability of TIS to stimulate type 1 conventional CD103 dendritic cells (DCs). We describe steps for isolating and differentiating CD103 DCs from murine bone marrow, inducing senescence in murine colon carcinoma cell line CT26, and coculturing DCs with SnCs. We then detail the flow cytometric analysis of DC maturation and activation. For complete details on the use and execution of this protocol, please refer to Liu et al. (2022) and Liu et al. (2023)..
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10751553 | PMC |
| http://dx.doi.org/10.1016/j.xpro.2023.102677 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!